Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

"Elon Musk is right," the senator tweeted. "The Pentagon, with a budget of $886 billion, just failed its 7th audit in a row.

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

We recently compiled a list of the Louis Navellier’s Top 10 Stock Picks Heading into 2025. In this article, we are going to ...

Novo Nordisk, a world-leading biopharmaceutical company, demonstrated its full industry chain layout in China, under the theme of "Driving change for generations, Healthy China", at the 2nd China ...

Approval announced for injection medication aimed at treatment for adults for obesity and risk of non-fatal myocardial ...

Investing.com -- Healthcare stocks in the U.S. and Europe have tumbled since Donald Trump’s election victory on November 5, with concerns rising over the potential policy impact of his cabinet picks, ...

Private insurance companies say U.S. patients aren't paying the true cost of expensive medications such as Wegovy and Zepbound, which can easily cost upwards of $1,000. Wegovy, the weight-loss ...

By late November, pharma groups such as Eli Lilly, Novartis and Vertex Pharmaceuticals had completed a total of 558 deals globally, worth a combined value of $67.2bn, the lowest level for that stage ...

It's the diabetes turned 'weight loss' drug that's gone viral in just a few short years. Ozempic has been steeped in ...

Hailing from Belgharia in Kolkata, 22-year-old Sayan Ghosh had traveled to Bangladesh on November 23. He stayed with a friend’s family.

For the first time in 30 years, a drug used to treat endometriosis will be listed on the pharmaceutical benefits scheme.